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The challenge
Leprosy is endemic in numerous poverty-affected communities. Many years usually pass
between an infection with Mycobacterium leprae and the onset of clinical signs of leprosy. The
inconspicuous first symptoms and slow progress of the disease often result in considerable
delay until the diagnosis is established and treatment initiated [1]. Contributing to this delay
are the generally weak health systems in areas where leprosy is endemic. Additionally, health
personnel are often unfamiliar with the cardinal signs of leprosy, which can lead to misdiagno-
ses [2].
The introduction of multi-drug therapy (MDT) in the 1980s has resulted in a massive
reduction of the number of registered leprosy patients [3, 4]. MDT drugs were first donated by
the Nippon Foundation (1995–1999) and since 2000 by Novartis. Following the global achieve-
ment of “leprosy elimination as a public health problem” in 2000, the efforts to actively identify
leprosy patients have been drastically scaled back in most countries. Instead, passive case
detection and integration of leprosy services into the general health system have become stan-
dard [5]. Unfortunately, achieving elimination as a public health problem has not halted lep-
rosy transmission [4, 5].
Close and long-term contact with an untreated leprosy patient is considered to be a major
risk factor for infection [6]. The administration of a single dose of rifampicin (SDR) as postex-
posure prophylaxis (PEP) to leprosy negative contacts of recently diagnosed patients has been
shown to reduce their risk of developing leprosy over the following years [7, 8]. The feasibility
and impact of a combination of contact tracing, screening, and PEP with SDR is currently
being evaluated in eight countries in the frame of the Leprosy Post-Exposure Prophylaxis
(LPEP) program [9, 10].
Cambodia declared leprosy elimination as a public health problem in 1998. Following this
milestone, leprosy control was largely halted, and the National Leprosy Elimination Program
(NLEP) atrophied. One decade later, a build-up of undiagnosed leprosy patients was observed,
and the concept of retrospective active case finding (RACF) campaigns or “drives” was devel-
oped. At its core, a drive is carried out by a mobile team of specifically trained leprosy experts
who systematically trace the leprosy patients diagnosed in an operational district (OD) and
screen their contacts. From 2011 until 2015, the contacts of all leprosy patients diagnosed
across Cambodia between 2001 and 2010 were screened in the frame of 11 drives [11].
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Recognizing the mutually complementing nature of routine passive case detection and RACF,
as well as interest in exploring the potential of PEP with SDR, the NLEP decided to pilot an
enhanced scheme in which SDR PEP is integrated into the drives. The objective is to evaluate
operational feasibility in a low-endemic setting to (a) maintain or revitalize contact tracing by
RACF and (b) integrate SDR PEP into RACF.
The solution
First, priority ODs for implementation of the project were identified by analyzing data for the
years 2011 through 2015 from the national leprosy database. A relatively high number of new
leprosy patients per 100,000 total population diagnosed in an OD over the period 2011
through 2015 was defined as the most important selection criterion. This is justified by the aim
of the project, namely, the screening of contacts of known recent patients to improve early
diagnosis and prompt treatment among this high risk group. By default, the top 25% of the
ranked OD list were selected as priority ODs. Additionally, three secondary criteria were
defined: (i) as an indication for the level of transmission: the proportion of children <15 years
among all leprosy patients in an OD, in which priority was given to the top quartile (25%) of
the values; (ii) as an indication for the level of diagnosis delay: the proportion of multibacillary
(MB) cases among all patients in an OD (top quartile); and (iii) as an indication for the level of
stigmatization: the proportion of women among all patients in an OD (bottom quartile). At
least two out of three secondary criteria needed to be fulfilled for the inclusion of an OD into
the list of priority ODs.
Applying these criteria, 31 out of all 78 ODs recognized at the time of the analysis were
selected (Table 1)
All leprosy patients (index patients) newly diagnosed in the priority ODs since 2011 and
still residing in a priority OD at the time of the drive are eligible for participation. The exact
number of resident index patients is determined in the frame of a predrive visit to the OD. The
contacts targeted in the frame of the project include household members of the index patients,
defined as individuals living in the same household as the index patient for at least 3 months
prior to the visit of the drive team, and the neighbors who are residing in the five households
located closest to the index patient’s household. To strengthen awareness and avoid absentee-
ism, the index patients and their contacts are informed of the drive and the exact time of the
Table 1. Number of ODs prioritized for inclusion in the RACF with SDR PEP project in Cambodia, stratified by
selection criteria.
Fulfilled inclusion criteria Number of ODs
Primary criterion1 20
Secondary criterion (subcriteria 2a2, 2b3, and 2c4) 1
Secondary criterion (subcriteria 2a and 2b only) 1
Secondary criterion (subcriteria 2a and 2c only) 1
Secondary criterion (subcriteria 2b and 2c only) 8
Total 31
1high number of new cases per 100,000 population.
2high proportion of child cases.
3high proportion of MB cases.
4low proportion of female cases.
Abbreviations: MB, multibacillary; OD, operational district; PEP, postexposure prophylaxis; RACF, retrospective
active case finding; SDR, single dose of rifampicin.
https://doi.org/10.1371/journal.pntd.0007039.t001
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home visit a few days prior to the drive. Upon arrival of the drive team in a household, the lep-
rosy patient is briefed about the aims, procedures, benefits, and potential risks of the interven-
tion, and written informed consent to disclose the disease status to all household members and
neighbors is sought. Upon signature, a list of all household members and neighbor contacts is
established. All listed individuals are informed about the program, procedures, the possible
consequences of the different screening outcomes (confirmed leprosy, suspect leprosy, leprosy
negative, which means the contact is potentially eligible for PEP with SDR) as well as on the
risks and benefits related to SDR administration. Contacts are then asked to provide informed
consent to participate in screening and SDR PEP, only the former, or withdraw from the
study.
A competent clinician embedded into the drive team can directly confirm leprosy diagno-
ses, upon which newly diagnosed patients are registered and start MDT as per the routine
NLEP guidelines. Screening-negative contacts are assessed for SDR eligibility against a list of
exclusion criteria and receive SDR at the appropriate dose [9]. Eligible contacts residing in a
household in which a new leprosy patient has been detected during the drive receive SDR only
one month after the start of MDT of the new patient. For this follow-up, a health center or dis-
trict staff returns to the household to reassess eligibility and administer the correct dose. An
individual SDR card with the contact identification, date, and rifampicin dose is handed out to
each participating contact. Last, SDR recipients are advised to seek care at the nearest health
facility should they develop any symptoms other than the known side effects of rifampicin
such as discoloration of urine.
The existing data collection and reporting system of the Cambodian NLEP is used to plan
the drives, and only drive-specific data—notably, contact details, informed consent, screening
and SDR administration—are recorded on separate forms. The drive data are entered into a
project database and integrated into the NLEP registry.
Outlook
The National Ethics Committee for Health Research of the Ministry of Health, Cambodia, has
approved the protocol on 26 August 2016. Following approval and a preparation phase, three
drives covering index patients living in 4 ODs had been implemented before the first interim
review of the project. In the frame of these drives, a total of 86 index patients had been traced
and 855 contacts consented to participate in screening. Among them, four new leprosy
patients were diagnosed and 828 contacts received SDR whereas 23 eligible contacts refused it
(2.7%). Another 508 contacts were absent at the time of the screening. Of note, absenteeism
decreased from 43.7% of the eligible contacts during the first drive to 26.2% during the third
drive. This improvement was achieved through more precise information of the index patients
and their contacts on the upcoming drive, and the arrangement of fixed appointments for the
passage of the drive team. Based on the emerging drives database, the feasibility of combining
RACF with SDR administration will be assessed in terms of coverage, screening participation,
and SDR refusal. The impact will be measured by monitoring the number and characteristics
of new leprosy patients identified through contact screening, the temporal evolution of the
number of new leprosy patients in the intervention areas, and the incidence of leprosy among
the contacts who had received SDR.
Adjustments will be necessary to make the approach relevant for other areas with low and
persisting leprosy endemicity, depending on the local health system organization and capacity.
Further operational research is also required to identify acceptable approaches to contact
screening and SDR administration in urban areas, in mobile populations, and in areas
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experiencing a high level of stigma. In addition, the most appropriate contact definition and
operational parameters remain to be determined for different settings.
More generally, the in-depth analysis of the data emerging from this project in Cambodia
will provide evidence on the feasibility and impact of the approach in low-resource and low-
endemicity areas, complementing the emerging evidence from the LPEP program [12]. Such
evidence is critical because over time, even more leprosy control programs will face a combina-
tion of low endemicity, reduced prominence, and a need to justify the costs of their work by
selecting the most efficient interventions to achieve leprosy morbidity control and—ultimately
—transmission interruption.
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